纯母乳饮食对早产儿肠道微生物组的影响:一项随机临床试验
这项在英国4个新生儿重症监护病房开展的随机临床试验,纳入胎龄小于30周、生后72小时内仅接受亲母乳的早产儿126例,比较纯母乳饮食(不足部分用巴氏消毒母乳、母乳来源强化剂)与牛乳配方及牛乳来源强化剂至矫正胎龄34周。共分析116例婴儿的472份粪便样本,两组细菌丰富度和香 Shannon 多样性随时间及34周时均无差异;纯母乳组乳杆菌相对丰度降低(系数估计0.056,P=0.03),但错误发现率校正后不显著。达到全量喂养时间、坏死性小肠结肠炎及其他关键新生儿疾病无差异。作者认为母乳来源产品的临床影响并非通过微生物组机制介导。
要点
- 纯母乳饮食组与牛乳组在矫正胎龄34周时肠道细菌丰富度和 Shannon 多样性均无差异,随时间变化也无差异。
- 纯母乳饮食组乳杆菌相对丰度降低(系数估计0.056,P=0.03),但错误发现率校正后不显著。
- 两组达到全量喂养时间、坏死性小肠结肠炎及其他关键新生儿疾病无差异。
- 作者认为母乳来源产品的临床影响并非通过微生物组机制介导。
适用人群与场景
- 胎龄小于30周、生后72小时内仅接受亲母乳的早产儿,来自英国4个新生儿重症监护病房,2017至2020年招募。
处置流程与药物剂量
- 干预组:纯母乳饮食,亲母乳不足时使用巴氏消毒母乳,并使用母乳来源强化剂,直至矫正胎龄34周。
- 对照组:使用牛乳配方和牛乳来源强化剂,直至矫正胎龄34周。
- 强化剂在耐受150 mL/kg/天不足48小时内开始。
研究设计与关键结果
- 随机临床试验,纳入126例早产儿,对照组63例(中位胎龄27.0周[IQR 26.0-28.1周],中位出生体重910 g[IQR 704-1054 g],男性32例[51%]),干预组63例(中位胎龄27.1周[IQR 25.7-28.1周],中位出生体重930 g[IQR 733-1095 g],男性38例[60%]);分析116例婴儿的472份粪便样本。
- 两组细菌丰富度或 Shannon 多样性随时间或矫正胎龄34周时均无差异。
- 纯母乳饮食组乳杆菌相对丰度降低(系数估计0.056;P=0.03),但错误发现率校正后不显著。
- 达到全量喂养时间、坏死性小肠结肠炎或其他关键新生儿疾病无差异。
证据类型、等级与局限
- 随机临床试验,在4个新生儿重症监护病房开展,微生物组分析对分组盲法。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,使用母乳来源配方和/或强化剂以实现纯母乳饮食对肠道细菌多样性整体指标无影响,但对既往与母乳接收相关的特定细菌分类群有影响;母乳来源产品的临床影响并非通过微生物组机制介导。
指南或共识出处
- ISRCTN trial registry identifier: ISRCTN16799022
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The effect of using an exclusive human milk diet compared with one that uses bovine products in preterm infants is uncertain, but some studies demonstrate lower rates of key neonatal morbidities. A potential mediating pathway is the gut microbiome.
OBJECTIVE: To determine the effect of an exclusive human milk diet on gut bacterial richness, diversity, and proportions of specific taxa in preterm infants from enrollment to 34 weeks' postmenstrual age.
DESIGN, SETTING, AND PARTICIPANTS: In this randomized clinical trial conducted at 4 neonatal intensive care units in the United Kingdom from 2017 to 2020, microbiome analyses were blind to group. Infants less than 30 weeks' gestation who had only received own mother's milk were recruited before 72 hours of age. Statistical analysis was performed from July 2019 to September 2021.
INTERVENTIONS: Exclusive human milk diet using pasteurized human milk for any shortfall in mother's own milk supply and human milk-derived fortifiers (intervention) compared with bovine formula and bovine-derived fortifier (control) until 34 weeks' postmenstrual age. Fortifier commenced less than 48 hours of tolerating 150 mL/kg per day.
MAIN OUTCOMES AND MEASURES: Gut microbiome profile including alpha and beta diversity, and presence of specific bacterial taxa.
RESULTS: Of 126 preterm infants enrolled in the study, 63 were randomized to control (median [IQR] gestation: 27.0 weeks [26.0-28.1 weeks]; median [IQR] birthweight: 910 g [704-1054 g]; 32 [51%] male) and 63 were randomized to intervention (median [IQR] gestation: 27.1 weeks [25.7-28.1 weeks]; median [IQR] birthweight: 930 g [733-1095 g]; 38 [60%] male); 472 stool samples from 116 infants were analyzed. There were no differences in bacterial richness or Shannon diversity over time, or at 34 weeks between trial groups. The exclusive human milk diet group had reduced relative abundance of Lactobacillus after adjustment for confounders (coefficient estimate, 0.056; P = .03), but not after false discovery rate adjustment. There were no differences in time to full feeds, necrotizing enterocolitis, or other key neonatal morbidities.
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial in preterm infants using human milk-derived formula and/or fortifier to enable an exclusive human milk diet, there were no effects on overall measures of gut bacterial diversity but there were effects on specific bacterial taxa previously associated with human milk receipt. These findings suggest that the clinical impact of human milk-derived products is not modulated via microbiomic mechanisms.
TRIAL REGISTRATION: ISRCTN trial registry identifier: ISRCTN16799022.
参考来源
- Embleton ND, Sproat T, Uthaya S, et al. Effect of an Exclusive Human Milk Diet on the Gut Microbiome in Preterm Infants: A Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 36857051. doi:10.1001/jamanetworkopen.2023.1165
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。